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INTRODUCTION
The combination of alkylating agents and cortico-
steroids has been the standard regimen for the management
of multiple myeloma (MM) [1,2]. Compared with standard
chemotherapy, high-dose chemotherapy followed by total
body irradiation (TBI) and autologous bone marrow trans-
plantation results in signiﬁcantly prolonged overall survival
of patients with newly diagnosed MM [3-5]. Several reports
of high-dose chemotherapy coupled with hematopoietic
stem cell support among heterogeneous cohorts of patients
with MM have suggested that the outcome in heavily
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ABSTRACT
In this prospective, multicenter, phase 2 study, multiple myeloma (MM) patients with primary resistant disease or
recurrent chemosensitive disease, in chemoresistant relapse, or in second or subsequent remission were treated
with high-dose chemoradiotherapy followed by autologous peripheral blood stem cell (PBSC) rescue. PBSCs were
collected using granulocyte-macrophage colony-stimulating factor (GM-CSF) 5 µg/kg per day subcutaneously for
3 days. Patients underwent high-dose chemoradiotherapy consisting of melphalan (140 mg/m2  1 day), cyclophos-
phamide (60 mg/kg per day  2 days), methylprednisolone (2 g/d  7 days), and total body radiation (150 cGy bid 
3 days) followed by peripheral blood stem cell reinfusion (≥1.2  109 mononucleated cells per kg) and GM-CSF
support (5 µg/kg per day) and were evaluated for response, survival, and toxicity. Thirty-six patients, median age
53.4 years, completed the study. The mean pretransplantation cumulative melphalan dose was 464 ± 72 mg. Exclud-
ing the 3 patients (8.3%) who failed to engraft, the median times to engraftment and platelet recovery were 10 days
(range, 8-39 days) and 17 days (range, 7-67 days), respectively. Four patients (11.1%) died of complications related
to the regimen (main causes of death, sepsis and acute respiratory distress syndrome) within the first 100 days.
Twenty-two patients (61.1%) achieved complete response (CR), 8 (22.2%) partial response, and 2 (5.5%) no
response. Two patients developed myelodysplastic syndrome after achieving CR. For all 36 patients, the probability
of overall survival at 5 years was 27.3%. Median survival was 31 months (range, 0.3-81 months) in all patients and
42 months (range, 3.4-81 months) in those with CR. The probabilities of overall and disease-free survival at 5 years
for the 22 patients who achieved CR were 43.6% and 15.7%, respectively. This high-dose chemotherapy regimen
coupled with PBSC rescue is associated with a high CR rate and is capable of inducing long-term survival in a sub-
set of heavily pretreated patients with primary resistant or recurrent MM.
KEY WORDS
Myeloma • Refractory • Transplantation • Radiotherapy
Biology of Blood and Marrow Transplantation 6:448-455 (2000)
© 2000 American Society for Blood and Marrow Transplantation ASBMT
H.M.L. was supported by National Cancer Institute Grant P30CA43703.
PBSC Transplantation in Relapsed/Refractory MM
449B B & M T
pretreated patients is generally poorer than in previously
untreated patients [6-9].
In the early 1980s, high-dose melphalan at 100 to
140 mg/m2 without stem cell support was ﬁrst introduced as
a salvage regimen for patients with refractory myeloma [10].
In 1986, Barlogie et al. [11] demonstrated that the hemato-
logic toxicity of this regimen could be signiﬁcantly reduced
by reinfusion of the patient’s hematopoietic stem cells.
Although high-dose chemotherapy and autologous trans-
plantation may be a better option for patients with primary
refractory disease or chemosensitive relapse [12,13], those
regimens have been reported to have limited efficacy in
patients with refractory relapse [6,13].
Numerous attempts are being made to improve the efﬁ-
cacy of salvage regimens [14], but studies exploring the efﬁ-
cacy of multidrug combinations in addition to high-dose
melphalan, with or without TBI, in the setting of relapse or
refractory disease have been few [15]; most efforts focus on
responsive myeloma patients [16,17]. We report the toxicity
and long-term outcome of a prospective, multicenter, phase 2
study in which heavily pretreated patients with relapsed or
primary resistant MM were treated with high-dose melphalan
(140 mg/m2) intensified with high-dose cyclophosphamide
(120 mg/kg) and methylprednisolone, followed by TBI
(900 cGy) and peripheral blood stem cell (PBSC) rescue.
PATIENTS AND METHODS
Eligibility Criteria
Between January 1992 and June 1995, consecutive
patients with MM between 18 and 70 years old at 3 institu-
tions (New England Medical Center, Boston, MA; Univer-
sity of Pennsylvania Cancer Center, Philadelphia, PA; and
Case Western Reserve University, Cleveland, OH) were
prospectively enrolled into the study if they were in
chemosensitive relapse (deﬁned as at least a 50% reduction
in myeloma protein in response to salvage chemotherapy),
had primary chemoresistant disease or were in chemoresis-
tant relapse (deﬁned as failure to respond to ﬁrst-line or sal-
vage chemotherapy with at least a 50% reduction in
myeloma protein), or were in second or subsequent remis-
sion [18]. Briefly, MM was diagnosed by the presence of
>10% plasma cells in the bone marrow aspirate or biopsy-
proven plasmacytoma, monoclonal immunoglobulin in the
serum, except in patients with nonsecretory MM, and radio-
logic evidence of osteolytic lesions. High-dose therapy with
hematopoietic stem cell support was approved by institu-
tional review boards, and all patients gave written informed
consent before enrollment. All patients underwent a multi-
gated radionuclide angiography scan or echocardiogram to
determine that they had a left ventricular ejection fraction of
>45% without dyskinesia. Patients were eligible if they had
an Eastern Cooperative Oncology Group performance status
of 0 or 1, pulmonary function testing with a carbon monox-
ide diffusion capacity (DLCO) and forced expiratory volume
(FEV1) >50% of predicted, and no laboratory or clinical evi-
dence of congestive heart failure. All patients were at least
4 weeks from prior chemotherapy before initiation of the
high-dose chemotherapy regimen. This prospective, multi-
center trial attempted to enroll all eligible patients. A log of
potentially eligible patients at each site was not recorded.
Patients who did not receive prior chemotherapy for
MM, those in plateau phase after achieving ﬁrst remission,
and those with plasma cell leukemia, localized plasmacy-
toma, smoldering myeloma [19], or benign monoclonal
gammopathy were excluded from the study. Patients who
had prior radiotherapy precluding TBI were considered
ineligible. Patients with recent myocardial infarction,
significant arrhythmia in the past 3 months, or hyperten-
sion requiring more than diuretics or -blockers were also
excluded.
Treatment Plan
Before peripheral stem cell collection, unpurged bone
marrow was harvested and cryopreserved to be used as a
backup if graft failure occurred. The harvested bone marrow
cells were cryopreserved in a final concentration of 10%
dimethylsulfoxide (DMSO) with a nucleated cell concentra-
tion of 2  107/mL, using a controlled-rate freezer, and
stored in liquid nitrogen at –196°C. Collection of a mini-
mum of 1  108 nucleated marrow cells per kg actual body
weight was required to proceed with PBSC collection and
later transplantation.
PBSC Harvest and Storage
Patients received granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) at a dose of 5 µg/kg per day subcuta-
neously starting 3 days before peripheral stem cell harvest and
continuing until completion of the harvest. Peripheral blood
mononuclear cells were collected using a cell separator (Cobe
Spectra, Lakewood, CO) by 4-hour (12-liter) continuous-
ﬂow leukapheresis. Collections were continued until a mini-
mum of 1.2  109 mononucleated cells per kg was obtained.
Analysis of CD34 content was not performed. The cell sus-
pension was diluted with autologous plasma to a concentra-
tion of 8  107 nucleated cells per mL and then with an equal
volume of freezing solution containing 10% irradiated autol-
ogous plasma, 20% DMSO, and 70% RPMI medium. The
cells were cryopreserved using a programmable freezer and
stored at –196°C. Samples for viability and culture were rou-
tinely obtained after processing.
High-Dose Chemoradiotherapy
The preparative regimen is described in Table 1. Doses
of chemotherapeutic agents were based on the lesser of
actual or corrected ideal body weight as calculated by ideal
weight + [0.25  (actual weight – ideal weight)].
Bone Marrow Reinfusion
Patients having engraftment failure, defined as an
absolute neutrophil count (ANC) <200/mm3 by day 30,
received their previously collected autologous marrow. Bags
of unpurged cryopreserved marrow cells were rapidly thawed
at the bedside by submersion in a 37°C water bath and
infused intravenously without additional ﬁltering or washing.
Supportive Care
Standard autograft supportive care was given. Patients
with a history of herpes simplex virus (HSV) infection or
seropositivity for HSV antibody received prophylaxis of
intravenous acyclovir 250 mg/m2 every 8 hours between
day –3 and day 14.
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Definition of Response
Complete response (CR) was defined as persistence of
all of the following criteria for at least 4 weeks: (1) <5%
plasma cells in a bone marrow sample with a cellularity of at
least 20%, (2) absence of monoclonal immunoglobulin in
the serum documented by immunofixation, (3) absence of
monoclonal immunoglobulin in urine documented by
immunofixation, (4) normal serum calcium, (5) no radio-
logic evidence of progression of lesions or new lesions, and
(6) resolution of plasmacytomas. Collapse of vertebral bod-
ies did not prevent categorization of CR.
Partial response (PR) was deﬁned as >50% reduction in
marrow plasmacytosis, monoclonal immunoglobulin in
serum or urine (<200 mg urinary M protein per 24 hours),
and >50% reduction in the sum of the products of perpen-
dicular diameters of all measurable-mass lesions without
evidence of progression in bone lesions and extramedullary
plasmacytomas.
Progressive disease was deﬁned as having >25% increase
in bone marrow plasmacytosis, monoclonal immunoglobulin
in serum or urine, and increasing bone lesions or develop-
ment of soft tissue plasmacytomas. Patients were considered
to have stable disease when their status did not satisfy the cri-
teria for partial remission or progressive disease.
Criteria for relapse after a CR were marrow plasmacy-
tosis of >10%, reappearance of hypercalcemia, an increase
in M protein to >2 g/dL in serum or 500 mg in a 24-hour
urine collection on 2 separate determinations 4 weeks apart,
new or progressive lytic lesions, or development of soft tis-
sue plasmacytomas.
Relapse after PR included (1) serum M protein more
than 2 times the lowest value achieved or 1 gram, whichever
was less, (2) reappearance of hypercalcemia, (3) marrow
plasmacytosis >10%, (4) new or progressive lytic lesions, or
(5) development of soft tissue plasmacytomas.
Toxicity Grading
National Cancer Institute (NCI) common toxicity crite-
ria were used to evaluate toxicity associated with the high-
dose chemotherapy regimen.
Statistical Analysis
Patients who remained free of recurrent disease after
PBSC transplantation were censored at the time of death or
most recent follow-up. The estimated incidence of disease
recurrence was determined using the nonparametric
Kaplan-Meier test for survival analysis (StatView 5.0 statisti-
cal software; SAS Institute, Cary, NC) [20]. Differences of
progression-free survival (PFS) rates between the risk
groups were assessed by univariate analysis using log rank
test, including calculation of 95% conﬁdence intervals.
RESULTS
Patient Characteristics
Relapsed/refractory patients with MM were treated
between January 1992 and June 1995. Characteristics of the
36 patients are summarized in Table 2. Eligible patients had
received melphalan-prednisone [1], high-dose dexametha-
sone [21], or vincristine-doxorubicin-dexamethasone (VAD)
[22] regimens before mobilization of hematopoietic stem
cells with GM-CSF. The patients had primary resistant dis-
ease (n = 14) or were in chemosensitive relapse (n = 12), sec-
ond or subsequent remission (n = 7), chemoresistant relapse
(n = 2), or untested second relapse (n = 1) at the time of
transplantation (Table 2). Median age at the time of trans-
plantation was 53.4 years (range, 35-66 years). These
patients represent a heavily pretreated group with a median
of 10 cycles of chemotherapy (range, 3-33 cycles) before
enrollment into the high-dose chemoradiotherapy protocol.
The pretransplantation cumulative melphalan dose was
464 ± 72 mg (mean ± SD) in the study group.
The mean time from diagnosis to hematopoietic stem
cell transplantation was 2.7 years. Median duration of post-
transplantation follow-up was 31 months (range, 0.3-81
months). Patients received peripheral blood progenitor cells
at a mean nucleated cell dose of 1.5 ± 0.09  109 per kg.
Response, Outcome and Survival
Of 32 patients evaluable for response (excluding the
4 patients with early treatment-related mortality), 22 (68.8%)
achieved CR and 8 (25%) PR, leading to an overall response
rate of 93.8% (83.3% if all 36 patients are considered). Two
patients did not respond (6.3%). Overall survival in the
36 patients completing the study was 27.3% at 5 years (Fig-
ure 1). In patients who achieved CR, overall survival was
45.5% at 5 years, which was signiﬁcantly better than the esti-
mated 0% survival at 4 years observed in partial responders
(chi-square = 7.11, P = .007) (Figure 2). Whereas the median
survival was 31 months (range, 0.3-81 months) for the study
Table 1. High-Dose Chemoradiotherapy Regimen*
Duration Agent Dose Route Total Dose
Day –7 Melphalan 140 mg/m2 Intravenous, over 1 h 140 mg/m2
Days –5 and –4 Cyclophosphamide† 60 mg/kg per day Intravenous, over 2 h 120 mg/kg
Day –3 to –1 Total body irradiation 150 cGy bid — 900 cGy
Day –7 to –1 Methylprednisolone 2000 mg/d Intravenous, over 5 min 14 g
Day 0 Stem cells 1.5 ± 0.09  109 NC/kg Intravenous, over 1-2 h 1.5 ± 0.09  109 NC/kg
From day 0‡ GM-CSF 5 mg/kg per day Subcutaneous or intravenous Various
*Doses of chemotherapeutic agents were based on the lesser of actual or corrected ideal body weight. NC indicates nucleated cell; GM-CSF,
granulocyte-macrophage colony-stimulating factor.
†Included aggressive hydration and bladder irrigation via urinary bladder Foley catheter during and after infusion.
‡Until absolute neutrophil count >1000/µL for 3 consecutive days.
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population, the 22 complete responders had a median sur-
vival of 42 months. Two patients developed myelodysplastic
syndrome (MDS) after achieving CR; in 1, the disease trans-
formed into acute myeloblastic leukemia on day 60. At this
writing, 9 patients are alive, either in relapse (n = 6) or CR
(n = 3), with survival periods ranging between 3.6 and 6.8 years.
Overall, 5 patients (13.9%) experienced treatment-
related mortality due to graft failure and transplant-related
complications. Of 36 patients, 3 (8.3%) failed to engraft.
These 3 patients were age >55 years and heavily pretreated
with melphalan (cumulative doses of 720, 1320, and
576 mg). Two of them received back-up marrow infusions
but died of progressive myeloma. The third patient with
engraftment failure, who did not receive back-up marrow,
died of a cerebral hemorrhage on day 103. In addition, there
were 4 early deaths from infection or bleeding during the
first 100 days after infusion of hematopoietic stem cells.
Overall transplant-related mortality (TRM) including early
deaths and late deaths due to engraftment failure was 13.9%
(5 patients). All patients had achieved at least the minimal
number of mononuclear cells via PBSC collection and mar-
row harvest for backup. All patients required <5 PBSC col-
lection sessions; no patients were excluded for failure to
undergo adequate collection. CD34 analysis was not per-
formed on stem cell collections.
Recurrence or Disease Progression
Median PFS in all responders was 20 months (range,
3-70 months). Complete responders had a median PFS of
23 months (range, 3-70 months), and the median PFS for
partial responders was 14 months (range, 5-46 months).
Estimated PFS in complete responders was 15.7% at
5 years. For partial responders, estimated PFS at 4 years
was 18.8% (Figure 3). Degree of response did not have a
significant effect on the duration of remission in our
patient group (P = .33, log rank test).
Toxicity of the Regimen
The median time to engraftment, deﬁned as ANC >500
 109/L, was 10.0 days (range, 8-39 days). The ANC
reached ≥1000  109/L on a median of day 12. Median time
to platelet recovery independent of transfusion support was
17.0 days (range, 7-67 days). By the NCI common toxicity
criteria, serious organ toxicity more severe than grade II was
infrequent. The most common grade III toxicities encoun-
tered were renal (17%), gastrointestinal (17%), and hepatic
(14%) (Table 3). Prior melphalan exposure (cumulative dose
>400 mg) did not affect time to white blood cell (WBC) or
platelet recovery (P = .84 and P = .21, respectively; Mann-
Whitney U test). Microbiologically documented severe
Table 2. Characteristics of 36 Patients With Relapsed/Refractory Myeloma
Parameter Value* Percentage






Time from diagnosis to 2.7/2.0 —
transplant, y




<400 mg 16 44.4













Monoclonal protein at 3.97 —
transplant, g/dL
2-Microglobulin at 3.37 —
transplant, mg/L
Serum albumin level, g/dL 3.87 —
Disease status at transplant
Primary resistant 14 38.8
Chemosensitive relapse 12 33.3
Second or subsequent remission 7 19.4
Chemoresistant relapse 2 5.5





Hypoplastic death 4 11.1
Progression-free survival, mo 20 (3-70) —
Complete responders 23.0 (3-70)† —
Partial responders 14.0 (5-46)† —
Overall survival, mo 31 (0.3-81) —
Complete responders 42 (3.4-81)‡ —
Partial responders 17 (12-46)‡ —
*Data are median (range), n, mean/median (range), or mean.
†P = .007.
‡P = .33.
Figure 1. Overall survival in 36 patients with relapsed/refractory myeloma.
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infections (grades III and IV) occurred in one-third of the
patients. Grade IV infection occurred in 2 patients (5.6%)
during the early posttransplantation period; the infections
consisted of Klebsiella oxytocia and polymicrobial septicemias
(Pseudomonas aeruginosa and Streptococcus viridans). Regimen-
related toxicity data are summarized in Table 3.
DISCUSSION
The use of high-dose therapy with stem cell support
has become increasingly common for patients with newly
diagnosed MM. Two recent large controlled trials have
demonstrated a survival advantage for this approach over
conventional therapy [3,23]. The use of this modality in
patients with relapsed or refractory myeloma is less well
established. Relapsed or primary resistant MM is associated
with a poor prognosis: patients failing to respond to primary
therapy typically have a median survival of 1 year with sal-
vage regimens, including palliative care and radiotherapy
[21]. The median survival in patients failing both melphalan
and the VAD regimen is less than a year [24]. The grave
prognosis associated with relapsed and refractory patients
with MM has led to several clinical investigations with high-
dose regimens. A chronological summary of high-dose ther-
apy coupled with autologous stem cell transplantation in the
primary resistant or relapsed/refractory group of patients is
depicted in Table 4 [6,8,12,13,25-33].
In these studies, the median survival for patients with
primary resistant MM ranges between 1 and 3 years. The
variability in the reported long-term survival rates is very
high (0% to 85%), most likely because of the small num-
bers of patients treated [6,12,26,27,29,33]. In these studies,
the number of patients with primary resistant MM ranges
between 12 and 30.
Patients with resistant relapse have the poorest out-
come, with a median survival of 6 to 12 months. Although
Jagannath et al. [25] initially reported a 21% 5-year survival
rate in the relapsed but refractory group, a poorer outcome
with overall survival rates of 0% and 8% was reported in
more recent studies [6,26]. Our series did not have enough
patients with resistant relapse for comparison.
The outcome after high-dose therapy and autologous
stem cell transplantation in patients with relapsed but
chemosensitive MM is less clear. After the promising 5-year
survival rate of 80% (n = 20) in myeloma patients with
chemosensitive relapses reported by Jagannath et al. [25],
2 subsequent studies reported inferior long-term survival
rates (10% [n = 11] and 22% [n = 30]) [6,26]. In a more
recent analysis of 1905 transplants reported to the European
Group for Blood and Marrow Transplantation, a CR rate of
52% was reported, with 25% overall and 20% progression-
free survival rates [34]. Median overall and progression-free
survival rates were 52 and 25 months, respectively. A sur-
vival disadvantage was noted for patients who received TBI.
In the most recent update reported by Barlogie et al. [13]
on the long-term follow-up of patients with advanced
MM, the 5-year survival rates after autologous stem cell
transplantation with different preparative regimens ranged
between 8% and 30%. The best results were noted with the
Figure 2. Comparison of overall survival rates with respect to
quality of response.
Figure 3. Comparison of progression-free survival rates with respect
to quality of response.
Table 3. Complications of the High-Dose Chemoradiotherapy Regimen*
Myelodysplastic syndrome 2 (5)
Hemorrhage 3 (11)
Congestive heart failure/arrhythmia 3 (11)
Renal failure†
Grade II 9 (25)
Grade III 6 (17)
Engraftment failure 3 (8)
Veno-occlusive disease 1 (3)
Diffuse alveolar hemorrhage 1 (3)
Hemorrhagic cystitis 1 (3)
Mucositis (grade ≥3) 9 (25)
Diarrhea (grade ≥3)† 1 (3)
Liver failure (total bilirubin)†
Grade III 12 (33)
Grade IV 5 (14)
Bacteremia 12 (33)
Hypoplastic death‡ 4 (11)
*Data are n (%). 
†National Cancer Institute common toxicity criteria.
‡Includes sepsis (n = 4) and hemorrhage (n = 1).
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combination of melphalan 140 mg/m2 and TBI. In the retro-
spective analysis, patients who received TBI as part of the
conditioning regimen had higher CR rates with relatively
longer event-free and overall survival, but a significant
change in TRM was not observed [13]. Once the changes in
supportive care were accounted for by the landmark analysis,
the intensity of the preparative regimen, including addition
of TBI, did not remain an independent favorable factor [13].
Our patients were heavily pretreated (mean of 12.5 prior
chemotherapy cycles, mean pretransplantation cumulative
melphalan dose of >400 mg, and elevated mean blood 2-
microglobulin level of >3 mg/L), with a mean of 2.7 years
from diagnosis to time of transplant. Despite these charac-
teristics, the CR rate (61.1%) and overall response rate
(83.3%) observed in our study are higher than in most of the
studies reported to date. Although this difference may be
related to the small sample size, after exclusion of patients
censored for TRM, the novel regimen that integrates high-
dose steroids may be responsible for the noted efficacy.
Indeed, high-dose corticosteroids are thought to be one of
the most active chemotherapeutic agents to induce rapid
tumor cytoreduction in the management of MM [35,36].
Cytogenetics, an important prognostic factor, was not
determined in these patients. Our reported median progression-
free and overall survival rates of 20 and 31 months, respec-
tively, compare favorably with rates reported in the most
recent retrospective analysis [13]. However, because of the
small sample size and lack of a randomized trial, it is cur-
rently unclear whether the higher CR rate observed in this
study would ultimately translate into better overall survival.
Our patients demonstrated a rapid WBC engraftment
(median, 10 days) and an early platelet recovery (median,
Table 4. Summary of Studies Employing High-Dose Chemotherapy With Hematopoietic Stem Cell Support in Primary Resistant or Recurrent Myeloma*
Median Median 5-y
Regimen n CR (%) PR (%) PFS, mo OS, mo Survival (%) ED (%) Reference Year
Mel + TBI or TT + TBI 41 14.6 NR 7-16 6-47 — 14.6 [24] 1990
Chemosensitive relapse 20 — — — — 80 (at 4 y) — — —
Resistant relapse 14 0 — 6 6 21 (at 4 y) 35.7 — —
CBV (primary resistant) 11 0 36 7 >12 NR 18 [30] 1990
Mel + TBI (primary resistant) 18 11 61 12 12 40 28 [26] 1992
BCNU + VP-16 + Mel ± Cy 63 17 63 43 59 43 11 [27] 1993
Refractory 44 — — — — — — — —
Chemosensitive 19 — — — — — — — —
BuCy + TT
Primary resistant and 27 11 44 NR NR — 14.8 [29] 1993
resistant relapse
Primary resistant 15 7 40 >24 — — 13 — —
BuCy + TT (primary resistant) 17 0 59 NR NR 85 (at 3 y) 6 [32] 1994
Mel or TT + TBI/BuCy + TT 49 — — — — — — [6] 1994
Primary resistant 15 0 40 17 39 0 13 — —
Chemosensitive relapse 11 40 20 12 36 10 9 — —
Resistant relapse 23 0 61 5 8 0 17 — —
Mel or TT + TBI/BuCy + TT 27 62 8 42 72 85 11 [12] 1994
(primary resistant)
Mel or TT + TBI — — — — — — — [31] 1994
Primary resistant + 21 10 — 8 16 28 24 — —
resistant relapse
Resistant relapse 14 0 — 4 7 28 36 — —
Mel ± TBI (primary resistant) 30 7 53 26 30 20 (at 4 y) 10 [28] 1995
BuCy ± mTBI/Bu + Mel† + 63 30 35 12 34 36 24 [8] 1996
TT (41 resistant patients)
Mel + TBI 75 32 58 — — — NR [25] 1998
Primary resistant 12 17 66 26 30 50 — — —
Chemosensitive relapse 30 39 57 13 21 22 — — —
Resistant relapse 33 30 56 7 12 8 — — —
Mel ± TBI, TT + TBI (all 63 13-27‡ 4-15‡ 8-24‡ 8-30‡ 0-13‡ [13] 1998
categories of advanced disease)
Mel + Cy + MP + TBI 36 61 22 28 31 27 11 This study —
Primary resistant 14 50 28 18 21 14 — — —
Chemosensitive relapse 19 68 21 20 41 37 — — —
*Studies reporting more than 10 patients excluding double transplants and purging are listed in chronological order. CR indicates complete
response; PR, partial response; PFS, progression-free survival; OS, overall survival; ED, early death; Mel, melphalan (140 mg/m2); TBI, total body
irradiation; TT, thiotepa; CBV, cyclophosphamide, BCNU, and etoposide; NR, not reported; BCNU, carmustine; VP-16, etoposide; Cy,
cyclophosphamide; Bu, busulfan; mTBI, modiﬁed total body irradiation; MP, methylprednisolone.
†Melphalan 100 mg/m2 instead of 140 mg/m2.
‡Depending on preparative regimen.
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17 days). The use of GM-CSF did not appear to be associated
with signiﬁcant toxicity. The regimen was associated with a
high 100-day mortality rate of 11.1%, compared with 7%
reported in the randomized study of autologous stem cell
transplantation performed in newly diagnosed patients [3]. A
signiﬁcant proportion of our patients experienced organ dys-
function (Table 3). This difference is likely related to the treat-
ment these patients received before transplantation. Although
well tolerated, our regimen was associated with a high inci-
dence of bacteremia and 4 septic deaths during the period of
treatment-induced hypoplasia. This ﬁnding may be related to
the use of TBI in conjunction with high-dose steroids.
Three patients failed to achieve hematopoietic reconstitu-
tion after stem cell reinfusion. All 3 patients were heavily pre-
treated with melphalan, which has been shown to decrease the
number of stem cells available for mobilization [37]. In addi-
tion, this study was performed before the routine use of CD34
analysis to determine the minimal number of stem cells for
transplantation. The use of chemotherapy as a mobilizing
agent has subsequently demonstrated enhanced CD34 collec-
tion compared with growth factor mobilization alone [38].
The frequency of MDS occurrence in our study (2 of
36 patients, 5.6%) is similar to the frequency of 6%
reported in a larger series of heavily pretreated patients with
myeloma undergoing autologous stem cell transplantation
[39]. It is generally believed that the therapy before trans-
plant is the likely cause of MDS in these patients [39].
In summary, we believe that the high-dose chemoradio-
therapy regimen consisting of cyclophosphamide, melphalan,
methylprednisolone, and TBI followed by peripheral blood
progenitor cell support is effective in the management of
patients with primary resistant or recurrent chemosensitive
MM. The regimen merits further investigation using currently
available stem cell mobilization methods and CD34 analysis.
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